Diversity, Equity, and Inclusion in Personalized Medicine: A Panel Discussion on How Personalized Medicine Can Improve Care for Diverse Patient Populations

On April 22, 2021, the Personalized Medicine Coalition convened a diverse panel of leaders from across the health care spectrum for a virtual discussion on topics related to health equity and personalized medicine. To further the cause of personalized medicine, the panelists explained, health care decision-makers must build a more diverse, equitable, and inclusive biomedical research enterprise. Doing so, they emphasized, is the only way to ensure that physicians and patients have reliable evidence about the ways in which various health care interventions may affect subsets of heterogenous patient populations. Broadening the reach of health care research will help ensure that health systems remain accountable and accessible to all.

The panelists also noted that personalized medicine calls for clinical interactions tailored more closely to patients’ circumstances, preferences, and cultural backgrounds.

“How we frame things has to be from the viewpoint of the person that is being served,” said one panelist. “That is why personalized medicine is the answer.”

How would health care for historically underserved patient populations look if key decision-makers stood four-square behind personalized medicine?

Health care leaders with expertise in engaging underserved communities will discuss.


  • Moderator

    James W. Lillard, Ph.D.
    Senior Associate Dean, Morehouse School of Medicine

  • Panelist

    Donna R. Cryer, J.D.
    President, CEO, Global Liver Institute, 27-year liver transplant recipient

  • Panelist

    Omar A. Escontrías, DrPH, MPH
    Vice President, Research, Education & Programs , National Health Council

  • Panelist

    Pari Johnston
    Vice President, Policy and Public Affairs, Genome Canada